These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

456 related items for PubMed ID: 21354226

  • 1. Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
    Tai WT, Cheng AL, Shiau CW, Huang HP, Huang JW, Chen PJ, Chen KF.
    J Hepatol; 2011 Nov; 55(5):1041-8. PubMed ID: 21354226
    [Abstract] [Full Text] [Related]

  • 2. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
    Tai WT, Cheng AL, Shiau CW, Liu CY, Ko CH, Lin MW, Chen PJ, Chen KF.
    Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308
    [Abstract] [Full Text] [Related]

  • 3. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY, Chao TT, Tai WT, Chang FY, Su WP, Chen YL, Chen PT, Weng CY, Yuan A, Shiau CW, Yu CJ, Chen KF.
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [Abstract] [Full Text] [Related]

  • 4. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY, Tai WT, Hsieh CY, Hsu WM, Lai YJ, Chen LJ, Shiau CW, Chen KF.
    Cancer Lett; 2014 Jul 28; 349(2):136-43. PubMed ID: 24735751
    [Abstract] [Full Text] [Related]

  • 5. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Br J Pharmacol; 2013 Feb 28; 168(3):658-72. PubMed ID: 22978563
    [Abstract] [Full Text] [Related]

  • 6. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF, Su JC, Liu CY, Huang JW, Chen KC, Chen WL, Tai WT, Shiau CW.
    Cancer Lett; 2012 Aug 01; 321(1):27-35. PubMed ID: 22465052
    [Abstract] [Full Text] [Related]

  • 7. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
    Tai WT, Shiau CW, Chen HL, Liu CY, Lin CS, Cheng AL, Chen PJ, Chen KF.
    Cell Death Dis; 2013 Feb 07; 4(2):e485. PubMed ID: 23392173
    [Abstract] [Full Text] [Related]

  • 8. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Liu CY, Tseng LM, Su JC, Chang KC, Chu PY, Tai WT, Shiau CW, Chen KF.
    Breast Cancer Res; 2013 Feb 07; 15(4):R63. PubMed ID: 23938089
    [Abstract] [Full Text] [Related]

  • 9. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI, Tai WT, Hung MH, Tsai MH, Chen MH, Chang MJ, Shiau CW, Chen KF.
    Cancer Lett; 2016 Feb 28; 371(2):205-13. PubMed ID: 26679051
    [Abstract] [Full Text] [Related]

  • 10. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3.
    Chen KF, Chen HL, Liu CY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Biochem Pharmacol; 2012 Mar 15; 83(6):769-77. PubMed ID: 22230479
    [Abstract] [Full Text] [Related]

  • 11. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT, Shiau CW, Chen PJ, Chu PY, Huang HP, Liu CY, Huang JW, Chen KF.
    Hepatology; 2014 Jan 15; 59(1):190-201. PubMed ID: 23908138
    [Abstract] [Full Text] [Related]

  • 12. Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.
    Chen KF, Tai WT, Hsu CY, Huang JW, Liu CY, Chen PJ, Kim I, Shiau CW.
    Eur J Med Chem; 2012 Sep 15; 55():220-7. PubMed ID: 22871485
    [Abstract] [Full Text] [Related]

  • 13. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT, Chu PY, Shiau CW, Chen YL, Li YS, Hung MH, Chen LJ, Chen PL, Su JC, Lin PY, Yu HC, Chen KF.
    Clin Cancer Res; 2014 Nov 15; 20(22):5768-76. PubMed ID: 25248379
    [Abstract] [Full Text] [Related]

  • 14. Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
    Huang CY, Lin CS, Tai WT, Hsieh CY, Shiau CW, Cheng AL, Chen KF.
    Int J Radiat Oncol Biol Phys; 2013 Jul 01; 86(3):456-62. PubMed ID: 23474115
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
    Gu FM, Li QL, Gao Q, Jiang JH, Huang XY, Pan JF, Fan J, Zhou J.
    World J Gastroenterol; 2011 Sep 14; 17(34):3922-32. PubMed ID: 22025881
    [Abstract] [Full Text] [Related]

  • 16. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity.
    Tai WT, Shiau CW, Li YS, Chang CW, Huang JW, Hsueh TT, Yu HC, Chen KF.
    J Hepatol; 2014 Jul 14; 61(1):89-97. PubMed ID: 24657398
    [Abstract] [Full Text] [Related]

  • 17. SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
    Su JC, Tseng PH, Wu SH, Hsu CY, Tai WT, Li YS, Chen IT, Liu CY, Chen KF, Shiau CW.
    Neoplasia; 2014 Jul 14; 16(7):595-605. PubMed ID: 25047655
    [Abstract] [Full Text] [Related]

  • 18. SC-1, a sorafenib derivative, shows anti-tumor effects in osteogenic sarcoma cells.
    Wang CT, Lin CS, Shiau CW, Chu PY, Hsiao CC, Chiang YL, Tai WT, Chen KF.
    J Orthop Res; 2013 Feb 14; 31(2):335-42. PubMed ID: 22926753
    [Abstract] [Full Text] [Related]

  • 19. Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
    Blechacz BR, Smoot RL, Bronk SF, Werneburg NW, Sirica AE, Gores GJ.
    Hepatology; 2009 Dec 14; 50(6):1861-70. PubMed ID: 19821497
    [Abstract] [Full Text] [Related]

  • 20. Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
    Hung MH, Tai WT, Shiau CW, Chen KF.
    World J Gastroenterol; 2014 Nov 07; 20(41):15269-74. PubMed ID: 25386075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.